History

    2017

  • Jun.

    In license China and South Africa rights for TYG 100 and TYG 200 from TYG in the UK

  • May.

    Matrix Partners China Invested 8 Million USD as part of the Series A round of funding.

  • Jan.

    Contract two commercial products from Shanghai RAAS and Harbin Pharma

    2016

  • Jun.

    In license China and South Africa rights for SPR 064 and SPR 965 from Sphaera Pharma a San Francisco based biotech company.

  • Jan.

    In license China and South Africa rights of development assets from Celleron Therapeutics Ltd an Oxford based biotech company.

    2015

  • Feb.

    Founder Mark Lotter interviewed by ChinaBio Today and Nuance would develop the drugs in both China and South Africa.

    2014

  • Dec.

    Successfully closes first round of seed funding.

  • Aug.

    Nuance Biotech Founded in Shanghai.

LINKS
Follow us
Copyright 2017-2018 NUANCE BIOTECH INC reserved. 沪ICP备17029781号
Address: Room 2106 Ciro's Plaza, 388 Nanjing Rd.(W) Shanghai China, 200003 Email: info@nuancebiotech.cn Tel: 021-32035318
  • 首页
  • 电话
  • 留言